Brian J. Hayes

Brian J. Hayes

Auto-generated profile, based on publicly available information

Brian J. Hayes

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2014 in Genome Research
Verified
Journal Article
Open access
PDF file
JIJanine O. Ilagan
Janine O. Ilagan
ARAravind Ramakrishnan
Aravind Ramakrishnan
BHBrian Hayes
Brian Hayes
MMMichele E. Murphy
Michele E. Murphy
AZAhmad S. Zebari
Ahmad S. Zebari
RBRobert K. Bradley
Robert K. Bradley
Whole-exome sequencing studies have identified common mutations affecting genes encoding components of the RNA splicing machinery in hematological malignancies. Here, we sought to determine how mutations affecting the 3′ splice site recognition factor U2AF1 alter its normal role in RNA splicing. We find that U2AF1 mutations influence the similarity of splicing programs in leukemias, but do not give rise to widespread splicing failure. U2AF1 mutations cause differential splicing of hundreds of genes, affecting biological pathways such as DNA methylation (DNMT3B), X chromosome inactivation (H2AFY), the DNA damage response (ATR, FANCA), and apoptosis (CASP8). We show that U2AF1 mutations alter the preferred 3′ splice site motif in patients, in cell culture, and in vitro. Mutations affecting the first and second zinc fingers give rise to different alterations in splice site preference and largely distinct downstream splicing programs. These allele-specific effects are consistent with a computationally predicted model of U2AF1 in complex with RNA. Our findings suggest that U2AF1 mutations contribute to pathogenesis by causing quantitative changes in splicing that affect diverse cellular pathways, and give insight into the normal function of U2AF1’s zinc finger domains.

6 December 2007 in Stem Cells
Verified
Journal Article
Closed access
PDF file
BHBrian Hayes
Brian Hayes
SFSara R. Fagerlie
Sara R. Fagerlie
ARAravind Ramakrishnan
Aravind Ramakrishnan
SBSzczepan Baran
Szczepan Baran
MHMichael Harkey
Michael Harkey
BTBeverly Torok-Storb
Beverly Torok-Storb
Canine embryonic stem (cES) cell lines were generated to establish a large-animal preclinical model for testing the safety and efficacy of embryonic stem (ES) cell-derived tissue replacement therapy. Putative cES cell lines were initiated from canine blastocysts harvested from natural matings. Times of harvest were estimated as 12–16 days after the presumed surge in circulating levels of luteinizing hormone. Four lines established from blastocysts harvested at days 13–14 postsurge satisfied most of the criteria for embryonic stem cells, whereas lines established after day 14 did not. One line, Fred Hutchinson dog (FHDO)-7, has been maintained through 34 passages and is presented here. FHDO-7 cells are alkaline phosphatase-positive and express both message and protein for the Oct4 transcription factor. They also express message for Nanog and telomerase but do not express message for Cdx2, which is associated with trophectoderm. Furthermore, they express a cluster of pluripotency-associated microRNAs (miRs) (miR-302b, miR-302c, and miR-367) characteristic of human and mouse ES cells. The FHDO-7 cells grow on feeder layers of modified mouse embryonic fibroblasts as flat colonies that resemble ES cells from mink, a close phylogenetic relative of dog. When cultured in nonadherent plates without feeders, the cells form embryoid bodies (EBs). Under various culture conditions, the EBs give rise to ectoderm-derived neuronal cells expressing γ-enolase and β3-tubulin; mesoderm-derived cells producing collagen IIA1, cartilage, and bone; and endoderm-derived cells expressing α-fetoprotein or Clara cell-specific protein. Disclosure of potential conflicts of interest is found at the end of this article.

11 July 2019 in Blood
Verified
Journal Article
Open access
PDF file
JHJasper Hsu
Jasper Hsu
ARAndreea Reilly
Andreea Reilly
BHBrian J. Hayes
Brian J. Hayes
CCCourtnee A. Clough
Courtnee A. Clough
EKEric Q Konnick
Eric Q Konnick
SDSergei Doulatov
Sergei Doulatov
Myeloid neoplasms, including myelodysplastic syndromes (MDS), are genetically heterogeneous disorders driven by clonal acquisition of somatic mutations in hematopoietic stem and progenitor cells (HPCs). The order of premalignant mutations and their impact on HPC self-renewal and differentiation remain poorly understood. We show that episomal reprogramming of MDS patient samples generates induced pluripotent stem cells from single premalignant cells with a partial complement of mutations, directly informing the temporal order of mutations in the individual patient. Reprogramming preferentially captured early subclones with fewer mutations, which were rare among single patient cells. To evaluate the functional impact of clonal evolution in individual patients, we differentiated isogenic MDS induced pluripotent stem cells harboring up to 4 successive clonal abnormalities recapitulating a progressive decrease in hematopoietic differentiation potential. SF3B1, in concert with epigenetic mutations, perturbed mitochondrial function leading to accumulation of damaged mitochondria during disease progression, resulting in apoptosis and ineffective erythropoiesis. Reprogramming also informed the order of premalignant mutations in patients with complex karyotype and identified 5q deletion as an early cytogenetic anomaly. The loss of chromosome 5q cooperated with TP53 mutations to perturb genome stability, promoting acquisition of structural and karyotypic abnormalities. Reprogramming thus enables molecular and functional interrogation of preleukemic clonal evolution, identifying mitochondrial function and chromosome stability as key pathways affected by acquisition of somatic mutations in MDS.

1 February 2011 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
JCJean S. Campbell
Jean S. Campbell
GAGretchen M. Argast
Gretchen M. Argast
SYSebastian Y. Yuen
Sebastian Y. Yuen
BHBrian Hayes
Brian Hayes
NFNelson Fausto
Nelson Fausto

25 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BHBrian J. Hayes
Brian J. Hayes
KRKimberly J. Riehle
Kimberly J. Riehle
MSMasami Shimizu-Albergine
Masami Shimizu-Albergine
RBRenay L. Bauer
Renay L. Bauer
KHKelly L. Hudkins
Kelly L. Hudkins
JCJean S. Campbell
Jean S. Campbell
Chronic liver injury leads to fibrosis, cirrhosis, and loss of liver function. Liver cirrhosis is the 12th leading cause of death in the United States, and it is the primary risk factor for developing liver cancer. Fibrosis and cirrhosis result from activation of hepatic stellate cells (HSCs), which are the primary collagen producing cell type in the liver. Here, we show that platelet-derived growth factor receptor α (PDGFRα) is expressed by human HSCs, and PDGFRα expression is elevated in human liver disease. Using a green fluorescent protein (GFP) reporter mouse strain, we evaluated the role of PDGFRα in liver disease in mice and found that mouse HSCs express PDGFRα and expression is upregulated during carbon tetrachloride (CCl4) induced liver injury and fibrosis injection. This fibrotic response is reduced in Pdgfrα heterozygous mice, consistent with the hypothesis that liver fibrosis requires upregulation and activation of PDGFRα. These results indicate that Pdgfrα expression is important in the fibrotic response to liver injury in humans and mice, and suggest that blocking PDGFRα–specific signaling pathways in HSCs may provide therapeutic benefit for patients with chronic liver disease.

9 August 2013 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
JWJocelyn H. Wright
Jocelyn H. Wright
MJMelissa M. Johnson
Melissa M. Johnson
MSMasami Shimizu‐Albergine
Masami Shimizu‐Albergine
RBRenay L. Bauer
Renay L. Bauer
BHBrian J. Hayes
Brian J. Hayes
JCJean S. Campbell
Jean S. Campbell
Cirrhosis is the primary risk factor for the development of hepatocellular carcinoma (HCC), yet the mechanisms by which cirrhosis predisposes to carcinogenesis are poorly understood. Using a mouse model that recapitulates many aspects of the pathophysiology of human liver disease, we explored the mechanisms by which changes in the liver microenvironment induce dysplasia and HCC. Hepatic expression of platelet‐derived growth factor C (PDGF‐C) induces progressive fibrosis, chronic inflammation, neoangiogenesis and sinusoidal congestion, as well as global changes in gene expression. Using reporter mice, immunofluorescence, immunohistochemistry and liver cell isolation, we demonstrate that receptors for PDGF‐CC are localized on hepatic stellate cells (HSCs), which proliferate, and transform into myofibroblast‐like cells that deposit extracellular matrix and lead to production of growth factors and cytokines. We demonstrate induction of cytokine genes at 2 months, and stromal cell‐derived hepatocyte growth factors that coincide with the onset of dysplasia at 4 months. Our results support a paracrine signaling model wherein hepatocyte‐derived PDGF‐C stimulates widespread HSC activation throughout the liver leading to chronic inflammation, liver injury and architectural changes. These complex changes to the liver microenvironment precede the development of HCC. Further, increased PDGF‐CC levels were observed in livers of patients with nonalcoholic fatty steatohepatitis and correlate with the stage of disease, suggesting a role for this growth factor in chronic liver disease in humans. PDGF‐C transgenic mice provide a unique model for the in vivo study of tumor–stromal interactions in the liver.